RxDoctor Payments Data

Jennifer Sharron, MD

Neurology · San Antonio, TXNPI 1093033698

Payments from drug & device makers

$20,754in general payments, 2019–2025

Across 1,174 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Acadia Pharmaceuticals Inc$1K
  • Neurocrine Biosciences, Inc.$1K
  • UCB, Inc.$934
  • Livanova USA, Inc.$863
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$440%
  • Travel & lodging$3091%
  • Food & beverage$20,36098%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)159$2,469
Teva Pharmaceuticals USA, Inc.88$1,130
Acadia Pharmaceuticals Inc82$1,056
Neurocrine Biosciences, Inc.60$1,006
UCB, Inc.37$934
Livanova USA, Inc.26$863
Novartis35$667
TG Therapeutics, Inc.41$653
EMD Serono, Inc.30$644
Biogen29$642
Supernus Pharmaceuticals, Inc.50$563
Genentech USA, Inc.23$539
AstraZeneca22$528
Pfizer41$518
Lundbeck LLC27$454
Bristol Myers Squibb22$436
Eisai Inc.21$429
Avanir Pharmaceuticals, Inc.23$406
Amgen24$392
Lilly USA, LLC21$375
Sanofi18$373
GE HealthCare16$318
MDD US Operations, LLC18$303
Argenx US, Inc.11$293
Impel Pharmaceuticals Inc.19$275
SK Life Science, Inc.13$272
Otsuka America Pharmaceutical, Inc.11$234
Acorda Therapeutics, Inc10$217
Jazz Pharmaceuticals Inc.7$216
CSL Behring11$206
Upsher-smith Laboratories LLC11$206
Johnson & Johnson(2 entities)9$176
Amneal Pharmaceuticals LLC9$167
Neurelis, Inc.5$159
Biohaven Pharmaceutical Holding Company Ltd.10$155
Arbor Pharmaceuticals, Inc.9$143
Corium, LLC8$133
Kyowa Kirin, Inc.7$132
Mallinckrodt Hospital Products Inc.6$125
Adamas Pharmaceuticals, Inc.7$120
Octapharma USA, Inc.6$114
Abbott5$109
Grifols USA, LLC5$105
Sunovion Pharmaceuticals Inc.12$96
Tanabe Pharma America, Inc.6$92
Merz Pharmaceuticals, LLC3$90
Boston Scientific3$82
Medtronic3$82
Vanda Pharmaceuticals Inc.3$79
Insightec,inc3$76
Assertio Therapeutics, Inc.5$76
Currax Pharmaceuticals LLC5$73
Scilex Pharmaceuticals Inc.4$72
Globus Medical1$66
GRT US Holding, Inc.3$66
E.r. Squibb & Sons, L.L.C.3$50
Avion Pharmaceuticals3$49
Azurity Pharmaceuticals, Inc.3$47
Axsome Therapeutics, Inc.2$42
ANI Pharmaceuticals, Inc.2$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,754 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$121,035
Medicare patients
409
Services billed
819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate59$282,224
IngrezzaValbenazine Tosylate20$158,370
Aimovig AutoinjectorErenumab-Aooe59$60,925
UbrelvyUbrogepant26$25,823
GocovriAmantadine Hcl14$23,866
BotoxOnabotulinumtoxina15$18,993
NeuproRotigotine18$17,843
QuliptaAtogepant11$11,678
Rivastigmine35$9,025
Dalfampridine ErDalfampridine21$7,263
Rasagiline Mesylate21$6,453
Memantine Hcl208$5,527
Levetiracetam147$4,737
Entacapone17$4,439
Divalproex Sodium ErDivalproex Sodium38$3,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,056$282,22459 claims
Neurocrine Biosciences, Inc.Ingrezza$1,006$158,37020 claims
AbbVieUbrelvy, Botox, Qulipta$2,469$56,49352 claims
MDD US Operations, LLCGocovri$303$23,86614 claims
UCB, Inc.Neupro$934$17,84318 claims
Upsher-smith Laboratories LLCTopiramate$206$81065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →